# Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype

Graphical Abstract

Authors

Natassia M. Vieira, Ingegerd Elvers, Matthew S. Alexander, ..., Kerstin Lindblad-Toh, Louis M. Kunkel, Mayana Zatz

Correspondence

kunkel@enders.tch.harvard.edu (L.M.K.), mayazatz@usp.br (M.Z.)

In Brief

The study of two exceptional dogs that escaped from the severe phenotype associated with dystrophin deficiency unveils a genetic modifier that allows functional muscle and normal lifespan despite the complete absence of dystrophin.

Highlights

- Escaper GRMD dogs show that a normal lifespan is possible without muscle dystrophin

- *Jagged1,* a Notch ligand, is upregulated in mildly affected dystrophin deficient dogs

- *Jagged1* overexpression can rescue the phenotype of dystrophin deficient zebrafish

Accession Numbers

GSE69040

Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype

Natassia M. Vieira,[1,2,3] Ingegerd Elvers,[4,5] Matthew S. Alexander,[1,2,6] Yuri B. Moreira,[7] Alal Eran,[2] Juliana P. Gomes,[3] Jamie L. Marshall,[1,2] Elinor K. Karlsson,[4,10] Sergio Verjovski-Almeida,[7,8] Kerstin Lindblad-Toh,[4,5,11] Louis M. Kunkel,[1,2,9,11,*] and Mayana Zatz[3,11,*]

[1]The Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA
[2]Department of Pediatrics and Genetics, Harvard Medical School, Boston, MA 02115, USA
[3]Human Genome and Stem Cell Center, Biosciences Institute, University of São Paulo, São Paulo 05508-090, Brazil
[4]Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA
[5]Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Box 597, 751 24, Uppsala, Sweden
[6]The Stem Cell Program at Boston Children's Hospital, Boston, MA 02115, USA
[7]Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil, 05508-000
[8]Instituto Butantan, São Paulo 05508-050, Brazil
[9]The Manton Center for Orphan Disease Research at Boston Children's Hospital, Boston, MA 02115, USA
[10]Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA
[11]Co-senior author
*Correspondence: kunkel@enders.tch.harvard.edu (L.M.K.), mayazatz@usp.br (M.Z.)
http://dx.doi.org/10.1016/j.cell.2015.10.049

SUMMARY

Duchenne muscular dystrophy (DMD), caused by mutations at the *dystrophin* gene, is the most common form of muscular dystrophy. There is no cure for DMD and current therapeutic approaches to restore dystrophin expression are only partially effective. The absence of dystrophin in muscle results in dysregulation of signaling pathways, which could be targets for disease therapy and drug discovery. Previously, we identified two exceptional Golden Retriever muscular dystrophy (GRMD) dogs that are mildly affected, have functional muscle, and normal lifespan despite the complete absence of dystrophin. Now, our data on linkage, whole-genome sequencing, and transcriptome analyses of these dogs compared to severely affected GRMD and control animals reveals that increased expression of *Jagged1* gene, a known regulator of the Notch signaling pathway, is a hallmark of the mild phenotype. Functional analyses demonstrate that *Jagged1* overexpression ameliorates the dystrophic phenotype, suggesting that *Jagged1* may represent a target for DMD therapy in a dystrophin-independent manner.

INTRODUCTION

Duchenne muscular dystrophy (DMD) is an X-linked disorder caused by mutations in *dystrophin* (Hoffman et al., 1987), which affects 1 in 3,500 to 5,000 boys (Axelsson et al., 2013; Mendell et al., 2012). Deficiency of muscle dystrophin causes progressive myofiber degeneration and muscle wasting (Hoffman et al., 1987). The first symptoms are usually evident at 3–5 years of age, with loss of ambulation between 9 and 12 years. Death occurs in the second or third decade due to respiratory or cardiac failure. While there are several treatments under development or currently in use—particularly corticotherapy, which aims to ameliorate symptoms and slow down the disease progression—there is still no cure for DMD (Bushby et al., 2010; Guiraud et al., 2015). Allelic to DMD, Becker muscular dystrophy (BMD) is caused by mutations that do not affect the reading frame of the *dystrophin* transcript; the result is a semi-functional, truncated dystrophin protein (Koenig et al., 1989). DMD muscle shows a complete absence of dystrophin, whereas in the BMD muscle there is a variable amount of partially functional dystrophin (Monaco et al., 1988). Differently from DMD, where most boys carrying null mutations show a severe phenotype, BMD patients show a variable clinical course. Genotype/phenotype correlation studies suggest that the severity of the phenotype is dependent on the amount of muscle dystrophin or the site of the mutation/deletion in the *dystrophin* gene (Koenig et al., 1989; Passos-Bueno et al., 1994; Vainzof et al., 1990)

DMD therapeutic approaches currently under development aim to rescue *dystrophin* expression in the muscle (Fairclough et al., 2013). Pre-clinical and clinical studies include exon-skipping (Goemans et al., 2011; Mendell et al., 2013; van Deutekom et al., 2007), AAV-delivery of μ-dystrophin (Mendell et al., 2010), and nonsense suppression to induce "readthrough" of nonsense mutations (Kayali et al., 2012). While AAV-delivery led to μ-dystrophin expression in skeletal muscle, T cell immunity against dystrophin epitopes was reported (Mendell et al., 2010). Also, the success of the dystrophin-based therapies relies on the quality of the recipient muscle. This requires the development of dystrophin-independent therapies to improve the muscle condition targeting the altered signaling pathways.

To explore the efficiency of the different therapeutic approaches for DMD, there is a need for animal models that mimic the human condition. However, animal models of dystrophin-deficiency

show differences in skeletal muscle pathology in response to dystrophin-deficiency (Bassett and Currie, 2004; Chapman et al., 1989; Im et al., 1996; Kornegay et al., 1988; Zucconi et al., 2010). The dystrophin-deficient fish model *sapje* shows some phenotypic variability, but nearly all fish die during the first weeks of life and all show abnormal muscle structure as measured by birefringence under polarized light (Bassett and Currie, 2004). The *mdx* mouse is the most widely used animal model for DMD, even though its mild phenotype does not mimic severe human DMD symptoms (Bulfield et al., 1984). The most similar to the human condition is the golden retriever muscular dystrophy (GRMD) dog (Bassett et al., 2003; Cooper et al., 1988; Kornegay et al., 1988; Sicinski et al., 1989). These animals carry a point mutation on a splicing site that causes the skipping of exon 7 and a premature stop codon, resulting in the absence of dystrophin. GRMD dogs and DMD patients share many similarities in disease pathogenesis, including early progressive muscle degeneration and atrophy, fibrosis, contractures, and grossly elevated serum creatine kinase (CK) levels (Kornegay et al., 1988; Sharp et al., 1992). Early death may occur within the first weeks of life but usually occurs around 1–2 years of age as a result of respiratory failure or cardiomyopathy. The great majority of GRMD dogs do not survive beyond age two. In the Brazilian GRMD colony at Biosciences Institute at the University of São Paulo, we have described two exceptional dogs presenting a very mild phenotype clearly distinguishable from other affected dogs despite the absence of muscle dystrophin. Histopathological and immunohistochemistry analysis of their muscle showed typical features of a dystrophic process with variability in fiber size, splitting, degeneration, and infiltrating connective tissue (Zucconi et al., 2010).

These two exceptional, related GRMD dogs (here called "escapers") remained fully ambulatory with normal lifespans, a phenotype never reported before for GRMD. They fall outside the known GRMD phenotypic range of variability, differing significantly from typically affected dogs despite their dystrophic muscle, absence of muscle dystrophin, elevated serum CK levels, and lack of evidence of utrophin upregulation (Zatz et al., 2015; Zucconi et al., 2010). Most importantly, these GRMD dogs show that it is possible to have a functional muscle in a mid-size dystrophin-deficient animal.

In this study, we set out to answer the following question: how do these escaper dogs have a fully functional muscle without dystrophin? Skeletal muscle of DMD patients undergoes waves or cycles of degeneration followed by regeneration. Muscle repair is a regulated process that comprises different cell types and signaling molecules, but additional factors and genetic modifiers involved in DMD pathogenesis remain poorly understood, representing new potential therapeutic targets. Genetic modifiers have been reported in DMD patients with a slower progression, but none were associated with a nearly normal phenotype (Flanigan et al., 2013). Here, through three independent approaches, we identified a modifier gene, *Jagged1*, which can modulate the GRMD phenotype. Using a mixed model association and linkage analysis, we identified a chromosomal region associated with the escaper phenotype. One gene within this region showed altered expression when comparing muscle tissue of escaper and affected dogs. By whole-genome sequencing, we found a variant present only in escaper GRMD dogs that

creates a novel myogenin binding site in the *Jagged1* promoter. Overexpression of *jagged1* in dystrophin deficient zebrafish rescues the dystrophic phenotype in this zebrafish model. This suggests that *Jagged1*, when increased in expression in muscle, can rescue dystrophin-deficient phenotypes in two different animal models, pointing to a new potential therapeutic target.

RESULTS

Escaper GRMD Dogs Share a Common Haplotype Different from Affected

To understand the genetic basis behind the escaper phenotype in GRMD dogs, we performed a genome-wide mapping analysis comparing two related escaper GRMD dogs—the only two GRMD escapers reported to date—to 31 severely affected GRMD dogs from the same breeding population. All GRMD dogs were confirmed to carry the originally described point mutation (a change from adenine to guanine transition) in the intron 6 of the *dystrophin* gene. This mutation ablates a splicing site and exon 7 is skipped from the mature mRNA. The absence of exon 7 causes a premature stop codon at exon 8 (Cooper et al., 1988; Sharp et al., 1992). Based on survival age and functional capacity, they were classified as escaper or affected (binary). All the dogs showing the standard range of phenotypic variability seen in GRMD dogs were classified as affected in this study. Our aim was to identify a single gene responsible for the milder phenotype seen in the two escaper dogs. We performed a two-step mapping analysis. First, we carried out an association study, utilizing the power of the many severely affected dogs expected to lack the modifier locus. This was followed by segregation analysis, taking advantage of the fact that the two escapers came from a well-defined pedigree in which a transmission-based test could be used. All dogs were genotyped using the Illumina CanineHD 170K SNP array. We tested for association genome wide using the mixed model approach implemented in EMMAX (Kang et al., 2010) to correct for population structure (Figure 1A) and identified strongly associated SNPs (p < 1×10^{-5}) on chromosomes 24, 33, and 37 (Figure 1B). We then measured identity by descent (IBD) across the genome between the two escapers using Beagle (Browning and Browning, 2007). Only the associated SNPs on chromosome 24 also overlapped a segment of IBD in the two escapers, consistent with a single origin of the causative mutation (Figure 1B). The 27 Mb segment showing both IBD and association with the escaper phenotype (CanFam2, cfa24:3,073,196-30,066,497) contains approximately 350 protein-coding genes. Linkage analysis using Merlin (Abecasis et al., 2002) strongly confirmed this region, with a maximal parametric LOD score of 3.31 (dominant inheritance model with complete penetrance, Figure S1). No other genomic regions showed any signs of linkage (Figure S2). Thus, convergent IBD, association, and linkage analyses all pointed to the same 27 Mb region on chromosome 24 (Figure 1C).

Muscle Gene Expression Profile of Escaper and Affected GRMD Dogs

We then performed a genome-wide analysis for genes differentially expressed in muscle between the escapers and affected dogs. Using Agilent mRNA SurePrint Canine arrays,

Figure 1. Combining Association, Linkage, and Identity-By-Descent Analysis Identifies a 30 Mb Candidate Region on Chromosome 24
(A) A QQ plot of 129,908 SNPs tested for association identified 27 SNPs outside the 95% confidence intervals (dashed lines) and minimal stratification relative to the expected distribution (red line), suggesting the mixed model approach corrected for close relatedness among the 2 escapers and 31 severely affected GRMD dogs.
(B) Only the association on chromosome 24 also falls in a region where the two escapers (sire and offspring) share a long haplotype likely to be identical-by-descent (IBD, red). Other peaks on chromosomes 24, 33, and 37 show no evidence of IBD (gray) and are most likely false positives due to the small sample size.
(C) The mapped region extends 27 Mb from the start of chromosome 24. Linkage analysis with Merlin (solid black line) detected a significant linkage peak (dominant parametric LOD > 3) overlapping the IBD and association peak that includes the putative driver gene *jagged1* (blue line) identified through gene expression profiling. See also Figures S1 and S2.

we compared muscle gene expression of the two escapers, four affected, and four wild-type dogs at two years of age. We found very similar muscle gene expression patterns in the two escaper GRMD dogs, which were more similar to muscle from wild-type dogs than from the affected dogs. In total, 114 genes were found to be differentially expressed between escapers and affected GRMD dogs, as shown by unsupervised hierarchical clustering of all ten samples (Figure 2A). Of these, 65 genes were also differentially expressed between escapers and wild-type dogs (Table S1), implicating them in a possible compensatory mechanism active in only the escaper dogs. Only one of these 65 genes, *Jagged1*, is located under the association peak on chromosome 24. *Jagged1* mRNA levels were two times higher in the escapers when compared to both wild-type and severely affected dogs (Figure 2B). Further protein level analysis confirmed the mRNA findings (Figure 2C).

Whole-Genome Sequence of Escaper Dogs
To identify potentially causative variants behind the differential gene expression pattern observed in the escaper dogs, we performed whole-genome sequencing on three dogs (the two escapers and one severely affected related dog). We hypothesized that the compensatory variation would be novel, as the escaper phenotype had not previously been seen in GRMD

dogs worldwide. We looked for variants located under the association peak on chromosome 24 and focused on the *Jagged1* locus (including 3 KB upstream and downstream of the gene) in search for a variant present only in the escapers and not in the affected GRMD dogs. A total of ~1,300 variants were detected within the escaper-associated region on chromosome 24. All variants were lifted over to the human genome, and those present in muscle enhancer regions near the promoters of the two isoforms of *Jagged1* expressed in skeletal muscle (Figure 3A) (Hoeppner et al., 2014) were further analyzed. Since the escaper variant was hypothesized to be novel, all variants detected in previous extensive canine sequencing efforts (Axelsson et al., 2013) were excluded. After this filtering, only a single point variant was found to follow the escaper haplotype: a heterozygote G>T change in the promoter region of *Jagged1* (cfa24:11655709, Figure 3A). Sanger sequencing of the *Jagged1* candidate escaper variant was performed in the escaper extended pedigree, including the first escaper (M1M4), his offspring, and a sibling's offspring (M1M5) (Figure S3). We also sequenced key breeders of the kennel and found that the variant is specific to the escapers' pedigree and was introduced in a single outcross (B1F3 mate). All affected dogs lacked the *Jagged1* variant, while both escapers were heterozygous. Thus, the novel *Jagged1* mutation segregates with the escaper phenotype in this family. Four additional individuals

Figure 2. Altered *Jagged1* Expression in Escaper GRMD Dogs

(A) mRNA microarray comparing muscle gene expression of escaper GRMD dogs with related severely affected and WT dogs.

(B) mRNA expression of escaper dogs confirming the expression array findings. Relative *Jagged1* gene expression in muscle samples of escaper GRMD dogs as compared to related severely affected and WT dogs; bars indicate SD from the mean.

(C) *Jagged1* protein levels in the muscle of escaper GRMD dogs (E) as compared to severely affected (A) and WT dog muscle (N); Beta-actin is the loading control. See also Table S1.

carried the candidate variant: three were stillborn puppies and the fourth was a GRMD puppy that died at 6 months of age from an accidental ingestion of a foreign object. This puppy (K2M11) was fully ambulatory with a similar phenotype to the two escaper dogs, but he was classified as affected in the mapping analysis since we cannot predict his adult phenotype with confidence.

Functional Analysis of Jagged1 Variant

To understand the effects of the escaper variant, we performed different functional analyses. This candidate variant was found to be conserved across 29 eutherian mammals, suggesting a regulatory potential for this region (Figures 3A and 3B). Transcription factor binding site analysis, using TRAP (Manke et al., 2010) and TRANSFAC (Matys et al., 2006), revealed that this G>T change creates a novel myogenin binding site (Figure 3C) with a high information content for the mutant allele (T) in the myogenin consensus binding motif (Figure 3D). Myogenin is a muscle-specific transcription factor involved in muscle differentiation and repair (Wright et al., 1989). To determine whether the variant affects DNA binding by myogenin, we carried out electrophoretic mobility shift assays (EMSAs) using muscle cell nuclear extracts and biotin-labeled oligonucleotide probes containing either the wild-type (WT) or escaper (E) genotype. The oligonucleotide probe containing the escaper T allele robustly bound the myogenin protein, whereas an oligonucleotide probe containing the WT G allele did not bind at all (Figure 3E). A competition assay showed that an unlabeled escaper probe efficiently competed with the binding of the labeled escaper probe. In contrast, the unlabeled WT probe had no effect on the binding activity of the labeled escaper probe, indicating a specific interaction between the escaper allele and myogenin (Figure 3E). To evaluate whether the novel myogenin binding site found in the escaper dogs was driving the increased expression of *Jagged1*, we performed a luciferase reporter assay using *Jagged1* upstream promoter sequences containing either the WT sequence or the escaper variant fused to a luciferase reporter. Luciferase vectors containing either WT or escaper sequence were transfected into muscle cells (myoblasts) and human embryonic kidney cells (HEK293T) along with constructs that overexpress either myogenin or another E-box myogenic factor (MyoD) as control. On HEK293K cells, overexpression of myogenin was able to activate the expression of the escaper *Jagged1* reporter 3-fold, but showed no activation of the WT reporter (Figure 3F). As predicted, the overexpression of MyoD did not activate either the WT or escaper *Jagged1* luciferase reporter (Figure 3F). Similarly, myoblasts (that endogenously express myogenin) transfected with the escaper vector showed a similar luciferase activation that was three times higher than the WT vector, notwithstanding the presence of overexpression vectors (Figure 3F). These results demonstrate that the creation of the novel myogenin binding site in the escaper *Jagged1* promoter is essential for driving the increase of *Jagged1* expression in the escaper dog skeletal muscles.

In Vivo Overexpression of Jagged1 Rescues sapje Muscle Phenotype

To evaluate if the overexpression of *Jagged1* can ameliorate the dystrophic muscle phenotype in other species, we used the severely affected dystrophic *sapje* zebrafish DMD model.

Figure 3. Variant Located in the *Jagged1* Promoter of Escaper GRMD Dogs

(A) Dog and Human *Jagged1* locus. Box: variant at dog chr24:11,644,709.

(B) Conservation of the variant position.

(C) Predicted transcription factor binding site at the region with the base pair change.

(D) Consensus sequence of myogenin binding site, demonstrating the high information content of the T allele.

(E) Electromobility shift assay (EMSA) showing myogenin binding to mutated probe (E) and not to the WT probe.

(F) Luciferase reporter assay showing activity of WT and E genotype vectors in both muscle cells (C2C12) and embryonic kidney cells (293T) with *Myogenin* or *MyoD* overexpression, as compared to empty vectors controls (V). Error bars indicate SEM (n = 3 replicates). See also Figure S3.

Muscle phenotype was assayed using birefringence, where fish are placed under a polarized light and dystrophin-negative fish show a decrease in the amount of light, indicative of muscle tearing or muscle fiber disorganization. In four separate experiments, we injected approximately 200 fertilized one-cell stage eggs from *sapje* heterozygous fish matings with mRNA of either

Figure 4. Functional Analysis of *jagged1* Expression

(A) Percent affected *sapje* fish as determined by birefringence assay at 4 dpf. Note fewer affected fish in the *jagged1* injected *sapje* cohort. Four separate injection experiments were performed.

(B) Genotype of *sapje* injected fish with *jagged1a* and *jagged1b* as compared to non-injected *sapje* fish. In red are dystrophin-null fish with a WT phenotype, recovered by *jagged1* overexpression.

(C) Immunofluorescence of *jagged1a* and *jagged1b* overexpression in the *sapje* fish. WT, phenotypically affected homozygous fish for the dystrophin mutation and *jagged1a* and *jagged1b* injected with normal birefringence (recovered) were stained for myosin heavy chain (MCH) and dystrophin antibodies. Note the organization of the muscle fibers in the recovered fish muscle comparable to the WT fish *(n = 10)* even without dystrophin. Photographs were taken at 20x magnification.

(D) *Jagged1* protein levels in the muscle of cardiotoxin injured mice one, four, and seven days after injury.

(E) *Jagged1* protein levels in muscle cells during in vitro muscle differentiation.

(F) Muscle cell proliferation rate, as measured by MTT, of two WT, two escaper, and two affected GRMD dogs. Error bars indicate SEM (n = 2, three replicates).

from the muscle lethality phenotype (Figure 4B). These results indicate that increasing *jagged1* expression rescues most dystrophin-null fish from developing the abnormalities typically seen in dystrophin-null muscle. To further evaluate the *jagged1a* and *jagged1b* overexpression *sapje* fish, we performed immunostaining on individual fish bodies using a myosin heavy chain (MHC) antibody to evaluate muscle structure. In WT fish, MHC was clearly expressed and showed that muscle fibers were normal. Interestingly, MHC staining of *jagged1* mRNA-injected dystrophin-null rescued fish showed normal myofiber structure similar to that of WT fish, whereas affected, non-injected

one of the zebrafish *jagged1* genetic copies of the mammalian *Jagged1* gene: *jagged1a* or *jagged1b*. In all experiments, an average of 24% of the non-injected *sapje* fish exhibited a typical affected dystrophic, patchy birefringence phenotype. This proportion is within the 21%–27% expected range of affected fish of a heterozygous *sapje* mating. In contrast, fish injected with either *jagged1a* or *jagged1b* showed a significantly lower percentage of fish with poor birefringence (p = 1.31×10^{-6} for *jagged1a*, p = 4.4×10^{-5} for *jagged1b*, Figure 4A). Genotypic analysis revealed that about 75% of dystrophin-null fish injected with *jagged1a* and 60% of of those injected with *jagged1b* had normal birefringence, which demonstrated a common rescue

dystrophin-null fish demonstrated clear muscle abnormalities (Figure 4C).

Jagged1 Expression during Muscle Regeneration and Cell Proliferation in Mice and Dogs

When examining the effect of *Jagged1* on muscle regeneration in normal mice, we found that *Jagged1* expression is upregulated at day 4 after cardiotoxin-induced injury in mouse tibialis anterior muscle (Figure 4D). We also determined that *Jagged1* is elevated during myoblast muscle differentiation in vitro (Figure 4E). To examine whether muscle cells from escaper dogs proliferate faster than cells from severely affected dogs, we performed a

proliferation assay using myogenic cells from biopsies of age-matched dogs. Escaper dogs' muscle showed typical dystrophic features (Zucconi et al., 2010) as evidenced by cycles of degeneration and regeneration, which is not seen in normal muscle. Because of these cycles and consistent activation, myogenic cells from affected GRMD dogs are expected to divide less frequently. We show that muscle cells from escaper dogs divide significantly faster than those from affected dogs (Figure 4F). These results are consistent with previous findings that show that overexpression of the Notch intracellular domain (NICD) expands the proliferative capacity of activated muscle satellite cells in vitro and in vivo (Wen et al., 2012).

DISCUSSION

Animal models for DMD are important tools for developing new therapeutic approaches. Among the different animal models for muscular dystrophy, the GRMD dog is the closest to the human condition. Both GRMD dogs and DMD patients have a severe phenotype as well as many phenotypic and biochemical similarities, including early progressive muscle degeneration and atrophy, fibrosis, contractures, and elevated serum creatine kinase levels. We identified two dogs that escaped from the typical severe phenotype associated with dystrophin deficiency. Using a combined approach of mapping and identity by descent, we identified a candidate region of association with the escaper phenotype. Only one gene within this region showed altered expression in escaper and affected dogs: *Jagged1*. We found a candidate variant at an upstream, conserved position creating a new muscle-specific transcription factor binding site that drives *Jagged1* overexpression. *Jagged1* is also in the region associated to the mild phenotype observed in a muscular dystrophy mouse model on the MRL (Murphy Roths Large) "superhealing" background. These mice show enhanced muscle regeneration and reduced dystrophic pathology. This healing phenotype was mapped to a region containing 49 genes that includes the *Jagged1* locus (Heydemann et al., 2012).

The role of *Jagged1* in skeletal muscle development and disease has yet to be fully elucidated. *Jagged1* is a Notch ligand (Lindsell et al., 1995). The Notch signaling pathway represents a central regulator of gene expression and is critical for cellular proliferation, differentiation, and apoptotic signaling during all stages of embryonic muscle development. The Notch pathway also plays an important role in muscle regeneration (Conboy and Rando, 2002; Wen et al., 2012), and overexpression of *Notch* has been shown to improve muscle regeneration in aged mice (Conboy et al., 2003). Moreover, Notch signaling has been shown to be dysregulated in muscle satellite cells and dystrophin-deficient muscles from *mdx* mice (Jiang et al., 2014). Additionally, there is an even more pronounced dysregulation of Notch signaling in the muscle satellite cell in the severe *mdx/utrn* double knockout mice (dKO) that have early lethality at two to four months due to a breakdown of the diaphragm muscles (Church et al., 2014; Mu et al., 2015). Here, we observed greater proliferative capacity of the escaper dogs' myoblasts, suggesting that *Jagged1* overexpression might be involved in muscle cell proliferation and repair. These results are consistent with

previous findings, which demonstrate that *Jagged1* overexpression stimulates cell proliferation, suggesting that *Jagged1*-based therapy might be able to induce regeneration in a tissue-specific manner (Collesi et al., 2008). Our data show that *Jagged1* expression is upregulated at day 4 after cardiotoxin-induced injury in mouse, a time point when myoblasts proliferate and fuse to promote muscle regeneration (Couteaux et al., 1988). Furthermore, Jagged1/Notch signaling has been shown to promote the expansion and differentiation capacity of bone marrow-derived stromal/stem cells (BMSCs) to promote skeletal regeneration (Dong et al., 2014). In endothelial cells, genetic *Jagged-1* overexpression resulted in endothelial branching of vasculature processes; while conversely, *Jagged-1* endothelial deletion blocked angiogenic growth in *Jagged-1* eKO mice (Pedrosa et al., 2015). Indeed, *Jagged-1* overexpression leads to the activation of vasculature progenitor cells from quiescence, in a manner similar to that of muscle satellite cell activation (Ottone et al., 2014). Thus, it is likely that the endogenous overexpression of *Jagged-1* that occurs in the muscles of the escaper dogs is driving myogenic cell proliferation and potential muscle growth that occurs in mesodermal lineages. A proof-of-principle experiment in which the Notch downstream transcription factor Rbp-jk was deleted in muscle satellite cells demonstrated that inhibition of Notch activation was detrimental to both muscle growth and muscle satellite cell expansion (Bjornson et al., 2012). All these findings suggest that *Jagged1* is likely to be a mediator of the regenerative process that is disrupted in dystrophin-deficient muscles and has potential as a novel therapy target to mitigate DMD pathological progression.

Although the great majority of DMD patients show a severe course, exceptional cases of dystrophin-deficient patients with a milder phenotype have been identified. We have previously reported two patients carrying null mutations, with no skeletal muscle dystrophin present via immunofluorescent staining or western blot analysis, and a milder course including the maintenance of ambulation well into their second decade of life (Zatz et al., 2014). More recently, a dystrophin-negative patient who remained ambulant until age 30 was also reported (Castro-Gago, 2015). Several other genetic modifiers are known to affect the severity of the clinical symptoms of Duchenne muscular dystrophy (*LTBP4*, *SPP1*, *TGFBR2*). However, none of these genetic variants have been shown to fully restore or delay substantially the symptoms of dystrophin-deficiency in DMD boys (Bello et al., 2012; Flanigan et al., 2013; Pegoraro et al., 2011; Piva et al., 2012). Furthermore, it would be of great interest to examine the genomes of DMD boys with varying clinical symptoms and determine if variants in *Jagged1* or other Notch signaling factors exist and are causative for any variation of the dystrophic disease progression. The Notch signaling pathway, specifically *Jagged1* overexpression, represents a novel therapeutic entry point for the treatment of DMD. Full restoration of Notch signaling must be achieved in the muscle satellite cell if one expects to correct the dysregulated Notch-dependent signaling that is affected in dystrophin-deficiency (Church et al., 2014). Direct injection of exogenous, soluble Jagged-1 ligand is not a viable therapeutic option, as external Jagged1 weakens Notch signaling even more than dystrophin-deficiency (Xiao et al., 2013). Thus, one might envision finding a small molecule or

transcription factor that could increase expression of *Jagged1* in all of the skeletal muscles of DMD patient.

There is currently no cure for DMD, and existing therapies aiming to rescue *dystrophin* expression are only partially effective. Here, we show that the overexpression of *Jagged1* is likely to modulate the dystrophic phenotype in dystrophin-deficient GRMD dogs. We also show that overexpression of *jagged1* rescues the dystrophic phenotype in a severe DMD model: the *sapje* zebrafish. Our study highlights the possibilities of across-species analysis to identify and validate disease-modifying genes and associated pathways. These results suggest that *Jagged1* may be a new target for DMD therapeutic efforts in a dystrophin-independent manner, which will complement existing approaches. In addition, further investigation on the gene target *Jagged1* will contribute to a better understanding of the disease pathogenesis and molecular physiology.

EXPERIMENTAL PROCEDURES

GRMD dogs were classified for this study in two groups based on full ambulatory capacity and survival age. The escapers group included the GRMD dogs that were fully ambulatory (can walk and run) at 9 years old. One escaper dog (M1M4) died at 11 years old from a cardiac arrest (Zatz et al., 2015) and the second one (H3M10) is now 9.5 years old and shows full ambulation. The affected group included the GRMD dogs that died before 5 years old with ambulatory difficulties, respiratory failure, and cardiopathy; this group includes stillbirths, neonatal death, and one dog that was full ambulatory when he died by ingesting a foreign object at 6-months-old (K2M11); all were confirmed to carry the GRMD mutation. DNA from GRMD dogs with and without the escaper phenotype was genotyped using the Illumina canine 170,000 SNP array and was compared using association, linkage, and IBD mapping. The threshold for genome-wide significance for each association analysis was defined based on the 95% confidence intervals (CIs) calculated from the beta distribution of observed p values, as previously described (Wellcome Trust Case Control, 2007). The likelihood of the two escapers being identity by descent (IBD) at each SNP was estimated based on haplotype frequencies in the full pedigree using Beagle 4 (release v4.r1274) with default parameter settings (Browning and Browning, 2007). Linkage analysis was performed using MERLIN (Abecasis et al., 2002) 1.1.2 to first remove inconsistent genotypes and then calculate LOD scores (logarithm of the odds ratios) using a dominant parametric model with complete penetrance. Expression analysis from the same dogs was performed using two-color microarray-based gene expression analysis. Genes differentially expressed between WT, escaper, and affected animals were identified with the significance analysis of microarray (SAM) statistical approach. False discovery rate (FDR) was 5%. Whole-genome sequencing was performed to 30x depth of three dogs (two escapers and one affected dog). Samples were sequenced on an Illumina HiSeq 2000, and sequencing reads were aligned to the CanFam 3.1 reference sequence using BWA. Following GATK base quality score recalibration, indel realignment, and duplicate removal, SNP and INDEL discovery was performed. To assess myogenin binding to candidate mutation, EMSA was performed using biotin labeled or unlabeled competitors probes and the LightShift Chemoluminescent EMSA kit (Thermo Scientific) following manufacturer's instructions. Luciferase reporter assay was performed cloning WT and GRMD dog *Jagged1* promoter region containing the G>T change into the pIRES-2a-hrGFP expression plasmid (Stratagene). HEK293T or C2C12 cells were transfected with affected or escaper 3′UTR jagged1-luc reporter constructs,Myogenin or MyoD overexpression plasmid, and renilla as internal control. Cells were lysed and assayed with luciferase substrate using the Dual Reporter Assay (Promega). Luciferase measurements were normalized to the renilla luciferase control on each well. Zebrafish were used for *jagged1* overexpression assay, where fertilized one-cell stage eggs from a *sapje* heterozygous fish mating were injected with mRNA from either one of the zebrafish *jagged1* gene copies: *jagged1a* or *jagged1b*. Zebrafish injected with either mRNA or non-injected

controls were assessed for phenotypic changes at 4 days post-fertilization (4dpf). Methods for cell growth assay and cardiotoxin injury are described in Supplemental Experimental Procedures

Supplemental Experimental Procedures are available as supplemental materials.

ACCESSION NUMBERS

The accession number for the gene expression data reported in this paper is GEO: GSE69040.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2015.10.049.

AUTHOR CONTRIBUTIONS

N.M.V, I.E., M.S.A., Y.B.M., S.V.-A., L.M.K., K.L.T., and M.Z. designed the study. N.M.V., Y.B.M., M.S.A., and J.L.M. performed experiments. N.M.V., I.E., Y.B.M., E.K.K., A.E., and K.L.T. performed data analysis and interpretation. N.M.V., I.E., K.L.T., L.M.K, and M.Z. wrote the paper with input from the other authors.

ACKNOWLEDGMENTS

REFERENCES

Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R. (2002). Merlin–rapid analysis of dense genetic maps using sparse gene flow trees. Nat. Genet. *30*, 97–101.

Axelsson, E., Ratnakumar, A., Arendt, M.L., Maqbool, K., Webster, M.T., Perloski, M., Liberg, O., Arnemo, J.M., Hedhammar, A., and Lindblad-Toh, K.

(2013). The genomic signature of dog domestication reveals adaptation to a starch-rich diet. Nature 495, 360–364.

Bassett, D., and Currie, P.D. (2004). Identification of a zebrafish model of muscular dystrophy. Clin. Exp. Pharmacol. Physiol. 31, 537–540.

Bassett, D.I., Bryson-Richardson, R.J., Daggett, D.F., Gautier, P., Keenan, D.G., and Currie, P.D. (2003). Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development 130, 5851–5860.

Bello, L., Piva, L., Barp, A., Taglia, A., Picillo, E., Vasco, G., Pane, M., Previtali, S.C., Torrente, Y., Gazzerro, E., et al. (2012). Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 79, 159–162.

Bjornson, C.R., Cheung, T.H., Liu, L., Tripathi, P.V., Steeper, K.M., and Rando, T.A. (2012). Notch signaling is necessary to maintain quiescence in adult muscle stem cells. Stem Cells 30, 232–242.

Browning, S.R., and Browning, B.L. (2007). Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am. J. Hum. Genet. 81, 1084–1097.

Bulfield, G., Siller, W.G., Wight, P.A., and Moore, K.J. (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA 81, 1189–1192.

Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P.R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al.; DMD Care Considerations Working Group (2010). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9, 177–189.

Castro-Gago, M. (2015). Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin. Neuromuscul. Disord. 25, 443.

Chapman, V.M., Miller, D.R., Armstrong, D., and Caskey, C.T. (1989). Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc. Natl. Acad. Sci. USA 86, 1292–1296.

Church, J.E., Trieu, J., Chee, A., Naim, T., Gehrig, S.M., Lamon, S., Angelini, C., Russell, A.P., and Lynch, G.S. (2014). Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy. Exp. Physiol. 99, 675–687.

Collesi, C., Zentilin, L., Sinagra, G., and Giacca, M. (2008). Notch1 signaling stimulates proliferation of immature cardiomyocytes. J. Cell Biol. 183, 117–128.

Conboy, I.M., and Rando, T.A. (2002). The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell 3, 397–409.

Conboy, I.M., Conboy, M.J., Smythe, G.M., and Rando, T.A. (2003). Notch-mediated restoration of regenerative potential to aged muscle. Science 302, 1575–1577.

Cooper, B.J., Winand, N.J., Stedman, H., Valentine, B.A., Hoffman, E.P., Kunkel, L.M., Scott, M.O., Fischbeck, K.H., Kornegay, J.N., Avery, R.J., et al. (1988). The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334, 154–156.

Couteaux, R., Mira, J.C., and d'Albis, A. (1988). Regeneration of muscles after cardiotoxin injury. I. Cytological aspects. Biol. Cell 62, 171–182.

Dong, Y., Long, T., Wang, C., Mirando, A.J., Chen, J., O'Keefe, R.J., and Hilton, M.J. (2014). NOTCH-Mediated Maintenance and Expansion of Human Bone Marrow Stromal/Stem Cells: A Technology Designed for Orthopedic Regenerative Medicine. Stem Cells Transl. Med. 3, 1456–1466.

Fairclough, R.J., Wood, M.J., and Davies, K.E. (2013). Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat. Rev. Genet. 14, 373–378.

Flanigan, K.M., Ceco, E., Lamar, K.M., Kaminoh, Y., Dunn, D.M., Mendell, J.R., King, W.M., Pestronk, A., Florence, J.M., Mathews, K.D., et al.; United Dystrophinopathy Project (2013). LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann. Neurol. 73, 481–488.

Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platenburg, G.J., Sipkens, J.A., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513–1522.

Guiraud, S., Aartsma-Rus, A., Vieira, N.M., Davies, K.E., van Ommen, G.J., and Kunkel, L.M. (2015). The Pathogenesis and Therapy of Muscular Dystrophies. Annu. Rev. Genomics Hum. Genet. 16, 281–308.

Heydemann, A., Swaggart, K.A., Kim, G.H., Holley-Cuthrell, J., Hadhazy, M., and McNally, E.M. (2012). The superhealing MRL background improves muscular dystrophy. Skelet. Muscle 2, 26.

Hoeppner, M.P., Lundquist, A., Pirun, M., Meadows, J.R., Zamani, N., Johnson, J., Sundström, G., Cook, A., FitzGerald, M.G., Swofford, R., et al. (2014). An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts. PLoS ONE 9, e91172.

Hoffman, E.P., Brown, R.H., Jr., and Kunkel, L.M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928.

Im, W.B., Phelps, S.F., Copen, E.H., Adams, E.G., Slightom, J.L., and Chamberlain, J.S. (1996). Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum. Mol. Genet. 5, 1149–1153.

Jiang, C., Wen, Y., Kuroda, K., Hannon, K., Rudnicki, M.A., and Kuang, S. (2014). Notch signaling deficiency underlies age-dependent depletion of satellite cells in muscular dystrophy. Dis. Model. Mech. 7, 997–1004.

Kang, H.M., Sul, J.H., Service, S.K., Zaitlen, N.A., Kong, S.Y., Freimer, N.B., Sabatti, C., and Eskin, E. (2010). Variance component model to account for sample structure in genome-wide association studies. Nat. Genet. 42, 348–354.

Kayali, R., Ku, J.M., Khitrov, G., Jung, M.E., Prikhodko, O., and Bertoni, C. (2012). Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum. Mol. Genet. 21, 4007–4020.

Koenig, M., Beggs, A.H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C.R., Lindlöf, M., Kaariainen, H., et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498–506.

Kornegay, J.N., Tuler, S.M., Miller, D.M., and Levesque, D.C. (1988). Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 11, 1056–1064.

Lindsell, C.E., Shawber, C.J., Boulter, J., and Weinmaster, G. (1995). Jagged: a mammalian ligand that activates Notch1. Cell 80, 909–917.

Manke, T., Heinig, M., and Vingron, M. (2010). Quantifying the effect of sequence variation on regulatory interactions. Hum. Mutat. 31, 477–483.

Matys, V., Kel-Margoulis, O.V., Fricke, E., Liebich, I., Land, S., Barre-Dirrie, A., Reuter, I., Chekmenev, D., Krull, M., Hornischer, K., et al. (2006). TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108–D110.

Mendell, J.R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429–1437.

Mendell, J.R., Shilling, C., Leslie, N.D., Flanigan, K.M., al-Dahhak, R., Gastier-Foster, J., Kneile, K., Dunn, D.M., Duval, B., Aoyagi, A., et al. (2012). Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 71, 304–313.

Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Kota, J., et al.; Eteplirsen Study Group (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637–647.

Monaco, A.P., Bertelson, C.J., Liechti-Gallati, S., Moser, H., and Kunkel, L.M. (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90–95.

Mu, X., Tang, Y., Lu, A., Takayama, K., Usas, A., Wang, B., Weiss, K., and Huard, J. (2015). The role of Notch signaling in muscle progenitor cell depletion and the rapid onset of histopathology in muscular dystrophy. Hum. Mol. Genet. 24, 2923–2937.

Ottone, C., Krusche, B., Whitby, A., Clements, M., Quadrato, G., Pitulescu, M.E., Adams, R.H., and Parrinello, S. (2014). Direct cell-cell contact with the vascular niche maintains quiescent neural stem cells. Nat. Cell Biol. 16, 1045–1056.

Passos-Bueno, M.R., Vainzof, M., Marie, S.K., and Zatz, M. (1994). Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. Hum. Mol. Genet. *3*, 919–922.

Pedrosa, A.R., Trindade, A., Fernandes, A.C., Carvalho, C., Gigante, J., Tavares, A.T., Diéguez-Hurtado, R., Yagita, H., Adams, R.H., and Duarte, A. (2015). Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1. Arterioscler. Thromb. Vasc. Biol. *35*, 1134–1146.

Pegoraro, E., Hoffman, E.P., Piva, L., Gavassini, B.F., Cagnin, S., Ermani, M., Bello, L., Soraru, G., Pacchioni, B., Bonifati, M.D., et al.; Cooperative International Neuromuscular Research Group (2011). SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology *76*, 219–226.

Piva, L., Gavassini, B.F., Bello, L., Fanin, M., Soraru, G., Barp, A., Ermani, M., Angelini, C., Hoffman, E.P., and Pegoraro, E. (2012). TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. J. Pathol. *228*, 251–259.

Sharp, N.J., Kornegay, J.N., Van Camp, S.D., Herbstreith, M.H., Secore, S.L., Kettle, S., Hung, W.Y., Constantinou, C.D., Dykstra, M.J., Roses, A.D., et al. (1992). An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics *13*, 115–121.

Sicinski, P., Geng, Y., Ryder-Cook, A.S., Barnard, E.A., Darlison, M.G., and Barnard, P.J. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science *244*, 1578–1580.

Vainzof, M., Pavanello, R.C., Pavanello Filho, I., Passos-Bueno, M.R., Rapaport, D., Hsi, C.T., and Zatz, M. (1990). Dystrophin immunostaining in muscles from patients with different types of muscular dystrophy: a Brazilian study. J. Neurol. Sci. *98*, 221–233.

van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. *357*, 2677–2686.

Wellcome Trust Case Control, C.; Wellcome Trust Case Control Consortium (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature *447*, 661–678.

Wen, Y., Bi, P., Liu, W., Asakura, A., Keller, C., and Kuang, S. (2012). Constitutive Notch activation upregulates Pax7 and promotes the self-renewal of skeletal muscle satellite cells. Mol. Cell. Biol. *32*, 2300–2311.

Wright, W.E., Sassoon, D.A., and Lin, V.K. (1989). Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell *56*, 607–617.

Xiao, Y., Gong, D., and Wang, W. (2013). Soluble JAGGED1 inhibits pulmonary hypertension by attenuating notch signaling. Arterioscler. Thromb. Vasc. Biol. *33*, 2733–2739.

Zatz, M., Pavanello, R.C., Lazar, M., Yamamoto, G.L., Lourenço, N.C., Cerqueira, A., Nogueira, L., and Vainzof, M. (2014). Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin. Neuromuscl. Disord. *24*, 986–989.

Zatz, M., Vieira, N.M., Zucconi, E., Pelatti, M., Gomes, J., Vainzof, M., Martins-Bach, A.B., Garcia Otaduy, M.C., Bento dos Santos, G., Amaro, E., Jr., et al. (2015). A normal life without muscle dystrophin. Neuromuscl. Disord. *25*, 371–374.

Zucconi, E., Valadares, M.C., Vieira, N.M., Bueno, C.R., Jr., Secco, M., Jazedje, T., da Silva, H.C., Vainzof, M., and Zatz, M. (2010). Ringo: discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog. Neuromuscl. Disord. *20*, 64–70.

Figure S1. Chromosome 24 Linkage Results, Related to Figure 1

(A) Linkage analysis of the escapers' pedigree identified a 27Mb linkage peak on chromosome 24 with a maximal parametric dominant LOD score of 3.31. A smoothed linkage curve (red) is shown on top of the single SNP LOD (gray). (B) Non-dog related *Jagged1* homologs all reside under this linkage peak. Shown are alignments of the human, bovine, rat, mouse, and frog *Jagged1* refseq sequences, as well as the two zebrafish homologs used in this study.

**Figure S2. Genome-wide Linkage Analysis Results, Related to Figure 1**

A single linkage peak was identified in the escapers' pedigree, mapping to chromosome cfa24:3,073,196-30,066,497 (CanFam2).

Figure S3. GRMD Dogs' Pedigree and Genotype, Related to Figure 3

All dogs were genotyped for the GRMD mutation and for the *jagged1* variant (G>T at Chr24: 11,655,709). Escaper dogs are: M1M4 and H3M10.

Jagged 1 Rescues the Duchenne

Muscular Dystrophy Phenotype

Natassia M. Vieira. Ingegerd Elvers, Matthew S. Alexander, Yuri B. Moreira, Alal Eran, Juliana P. Gomes, Jamie L. Marshall, Elinor K. Karlsson, Sergio Verjovski-Almeida, Kerstin Lindblad-Toh, Louis M. Kunkel,and Mayana Zatz

Supplemental Methods

GRMD dogs

All animals were housed and cared for in the University of São Paulo and genotyped at birth for the GRMD mutation as previously described (Honeyman et al., 1999). GRMD dogs were identified by microchip implants. Animal care and experiments were performed in accordance with animal research ethics committee of the Biosciences Institute, University of São Paulo (034/2005).

GRMD dog phenotype

Typically, 80% of GRMD dogs die before 18 months old and severely affected dogs do not survive past 5 years (Zucconi et al., 2009). At 4 months of age all severely affected GRMD dogs show clear clinical signs resulting from muscle degeneration with difficulty to ambulate. The two dogs here called escapers are clearly distinguishable from the other GRMD dogs: they survived and remained fully ambulatory beyond the known range of the GRMD phenotypic variability. Given this major phenotype difference, GRMD dogs were classified for this study in two groups based on full ambulatory capacity and survival age. Escapers group: GRMD dogs that were fully ambulatory (can walk and run) at 9 years old. One escaper dog (M1M4) died at 11 years old from a cardiac arrest (Zatz et al., 2015) and the second one (H3M10) is now $9^{1/2}$ years old and shows full ambulation (can walk and run). Affected group: dogs that died before 5 years old with difficulties in walking, deglutition, respiratory failure or cardiomyopathy as well as stillbirths and neonatal death (confirmed to carry the GRMD mutation).
One offspring that carried the candidate mutation (K2M11) and died at age 6 months from ingestion of a foreign object showed a similar phenotype as the two escaper dogs and was fully ambulatory. Hence, he is potentially an escaper, consistent with his genotype, but his early death makes it impossible to confirm this. He was classified as an affected dog for the genomewide association analysis, based on the phenotype criteria described above.

Comparison of affected and escaper animals in the pedigree using the Illumina 170K canine array

DNA from all GRMD dogs from the pedigree (Supplemental Figure 3) was isolated from blood and genotyped using the Illumina 170K canine HD array. Badly genotyped individuals and lowly genotyped SNPs were filtered out using Plink (PLINK http://pngu.mgh.harvard.edu/purcell/plink/), leaving 2 escapers, 31 affected (offspring of M1M4 and M1M5). EMMAX (Kang et al., 2010) was used to simultaneously correct for population structure and relatedness in the pedigree using a linear mixed model approach (Kang et al., 2010) applied to a binary phenotype (escaper vs. affected) as described in the EMMAX documentation. The threshold for genome-wide significance for each association analysis was defined based on the 95% confidence intervals (CIs) calculated from the beta distribution of observed p values, as previously described (Wellcome Trust Case Control, 2007). The likelihood of the two escapers being Identity By Descent (IBD) at each SNP was estimated, based on haplotype frequencies in the full pedigree, using Beagle 4 (release v4.r1274) with default parameter settings (Browning and Browning, 2007).

Linkage analysis
Linkage analysis was performed on the same SNP dataset described above. First, we used PedCut (Liu et al., 2008) to identify a smaller, computationally feasible sub-pedigree, without loss of information, as the original pedigree size was computationally intractable for linkage analysis. The resulting sub-pedigree was composed of 15 dogs: two escapers and 13 affected dogs. MERLIN (Abecasis et al., 2002) 1.1.2 was used to first remove inconsistent genotypes and then calculate LOD scores (logarithm of the odds ratios) using a dominant parametric model with complete penetrance.

mRNA expression profiling
Total mRNA was extracted from two escaper, four affected GRMD dogs, and four wild-type dogs, all age-matched muscle biopsies. Sample labeling and array hybridization were performed according to the Two-Color Microarray-Based Gene Expression Analysis—Low Input Quick Amp Labeling—protocol (Agilent Technologies) using the SurePrint Canine 4x44K (Agilent Technologies) Microarray (GEO Platform GPL11351). Samples were labeled with Cy5 and a single RNA from a wild-type individual was labeled with Cy3 and used as a common reference on all arrays. A dye-swap technical replicates approach was also applied, where all samples were labeled with Cy3 and the reference RNA was labeled with Cy5. Labeled cRNA was hybridized using Gene Expression Hybridization Kit (Agilent). Slides were washed and processed according to the Agilent Two-Color Microarray-Based Gene Expression Analysis protocol (Version 5.5) and scanned on a GenePix 4000 B scanner (Molecular Devices, Sunnyvale, CA, USA). Fluorescence intensities were extracted using Feature Extraction (FE) software (version 9.0; Agilent). Averaged values of dye-swap technical replicates were used for further analysis. Genes differentially expressed between wild-type, escaper, and affected animals were identified with the Significance Analysis of Microarray (SAM) statistical approach (Tusher et al., 2001), using the following parameters: one-class unpaired responses, t-statistic, 100 permutations. False discovery rate (FDR) was 5%. Gene Expression data were deposited at GEO database under Accession Number GSE69040.

Whole genome sequencing and variant calling
Whole-genome sequencing was performed to 30x depth of three dogs (two escapers and one severely affected related dog). Samples were sequenced on an Illumina HiSeq 2000, sequencing reads were aligned to the CanFam 3.1 reference sequence using BWA(Li and Durbin, 2010). SNPs and indel variants were called following GATK (McKenna et al., 2010) Best Practices recommendations (DePristo et al., 2011); including base quality score recalibration, indel realignment, duplicate removal, HaplotypeCaller, variant quality score recalibration, and variant filtration using standard hard filtering parameters. Variants were called in the *jagged1* gene including the 3KB regions upstream and downstream of the gene (chr24:11654000-11696000, canfam3).

Variants were then filtered aiming to find a new mutation present only in the escaper GRMD dogs and not in the affected siblings or previous canine SNP data sets (Axelsson et al., 2013) using a custom PERL script. Variants were lifted-over to human genome using UCSC Genome Browser (Kent et al., 2002). Variants present in muscle regulatory regions (ENCODE) (Rosenbloom et al., 2013) were considered of interest if they had not previously been reported in other unrelated dogs. To verify the segregation of the variant, genomic DNA from GRMD dogs related to the first escaper was amplified by PCR using the following primers: forward primer 5'-ACCCAACCTTTTCTGCACTC-3' and reverse primer 5'-CATAGCCAAGGTCGAAGGAA-3', with a 55 °C annealing

temperature and 35 cycles. PCR products were purified using ExoSap (Affymetrix) and sequenced at The Molecular Genetics Core Facility at Boston Children's Hospital.

Electrophoretic mobility shift assay (EMSA)
The duplex DNAs obtained by annealing of complementary oligonucleotides were either biotin labeled or unlabeled competitors. Probes sequence were: WT: CTCCTTTATTTCAGCGGAACTAAAGAAGTCTC and for the variant CTCCTTTATTTCAGCTGAACTAAAGAAGTCTC. Biotin-labeled probes (0.5pmol) were incubated with C2C12 nuclear extract (Active Motif) on ice for 20min in the reaction buffer (10mM Tris (pH 7.5), 50mM KCl, 1mM EDTA, 1mM DTT, 50% glycerol, 50ng/ul of poly (dI.dC) and 10ug/ul of bovine serum albumin). For competition experiments, unlabeled competitor DNAs in 100-fold molar excess over the labeled probe were included in the binding reactions. The supershift assay was performed with 5ug of anti-myogenin F5D (Santa Cruz Biotechnology) mouse monoclonal antibody incubated 30 min at room temperature. Anti-mouse IgG (Abcam) was used as control antibody. Samples were loaded onto 6% DNA Retardation Gels (Invitrogen) and separated at 10 V/cm in 0.5 TBE (45 mM Tris, 45 mM borate, 1 mM EDTA). Transfer to positive charged nylon membrane (GE – Hybond-N$^+$) was performed in 0.5 TBE at 5°C for 1 hour at 380 mA. Membrane crosslink was performed at 120mJ/cm^2. Detection of the biotin-labeled DNA was carried out by chemiluminescence using LightShift Chemoluminescent EMSA kit (Thermo Scientific) following manufacturer's instructions.

Luciferase reporter assays
The wild type and GRMD dog *Jagged1* promoter region containing the G>T change at dog chr24:11644709 were amplified from affected and escaper dogs DNA. Amplicons were then cloned into the pGL4.10 vector (Promega). Human MYOD1 (NCBI Ref. NM_002478.4) and MYOG (NM_002479.5) EST open reading frame clones (Open Biosystems) were amplified and cloned into the pIRES-2a-hrGFP expression plasmid (Stratagene). The luciferase reporter assay was performed by first plating 10,000 HEK293T or C2C12 cells/well into 96-well plates. The following day the cells were transfected using Lipofectamine 3000 reagent with 90 ng of affected or escaper 3'UTR jagged1-luc reporter constructs and 100 ng of Myogenin or MyoD overexpression plasmid and 10ng of renilla as internal control. Forty-eight hours after transfection the cells were lysed in Reporter Lysis Buffer (Promega), and 20 µL of whole cell lysate were assayed with 25 µL of luciferase substrate using the Dual Reporter Assay (Promega). Luciferase levels were measured on a plate luminometer. Luciferase measurements were normalized to the renilla luciferase control on each well. Experimental samples were run and analyzed in triplicate.

Zebrafish lines
Zebrafish were housed in the Boston Children's Hospital Aquatics facility (Director Christian Lawrence) under the animal protocol number: 09-10-1534R and maintained as breeding stocks as previously described (Lawrence and Mason, 2012).

Sapje Genotyping
Genomic DNA extracted from injected fish (Meeker et al., 2007) and controls was amplified with for *sapje* mutation: forward primer 5′-CTGGTTACATTCTGAGAGACTTTC-3′ and reverse primer 5′-AGCCAGCTGAACCAATTAACTCAC-3′, with a 52 °C annealing temperature and 35 cycles. PCR products were purified using ExoSap (Affymetrix) and sequenced at The Molecular Genetics Core Facility at Children's Hospital Boston.

Zebrafish *jagged1* overexpression

Fertilized one-cell stage eggs from a *sapje* heterozygous fish mating were injected with 20 pg of mRNA of either one of the zebrafish jagged1 gene copies: *jagged1a* or *jagged1b*. Plasmid constructs were kindly provided by Dr. Itoh from Nagoya University (Yamamoto et al., 2010) and linearized by Not1 restriction digestion. mRNA was synthesized with SP6 message machine kit (AMBION) and purified with mini Quick Spin Columns (Roche). Overexpression of zebrafish *jagged1* was confirmed by western blot for HA tag (data not shown). Zebrafish injected with either mRNA and non-injected controls and assessed for phenotypic changes at 4 days post fertilization (4dpf). Each injection was performed four times. Approximately 200 embryos were injected at each dosage in four separate experiments.

Zebrafish Birefringence assay

The typical *sapje* dystrophic muscle phenotype was detected by using a birefringence assay, a technique used to analyze muscle quality due to the unique ability of highly organized sarcomeres to rotate polarized light. The birefringence assay is performed by placing anesthetized embryos on a glass polarizing filter and covering them with a second polarizing filter. The filters are placed on a bottom-lit dissection scope and the top polarizing filter is twisted until the light refracting through the zebrafish's striated muscle is visible.

Zebrafish Immunostaining

Immunostaining was performed in 4dpf embryos. Embryos were fixed in 4% paraformaldehyde (PFA) in PBS at 4°C overnight and dehydrated in 100% methanol. After rehydration, 4 dpf embryos were incubated in 0.1% collagenase (Sigma) in PBS for 60 min. Blocking solution containing 0.2% saponin was used for 4 dpf embryos. Anti-slow muscle myosin heavy chain antibody (F59, Developmental Studies Hybridoma Bank; 1:50) was used. The embryos were placed in 3% methyl cellulose or mounted on a glass slide and observed with fluorescent microscopes (Nikon Eclipse E1000 and Zeiss Axioplan2).

Western Blot

Muscle sample proteins were extracted using RIPA buffer with proteinase inhibitor tablets (Roche). Samples were centrifuged at 13,000g for 10 minutes to remove insoluble debris. Soluble proteins were resolved using electrophoresis with Novex 4–20% Tris-Glycine gels (Life Technologies), and transferred to nitrocellulose membranes (Hybond; Amersham Biosciences). All membranes were stained with Ponceau (Sigma-Aldrich) to evaluate the amount of loaded proteins. Blots were blocked for 1 hour in Tris-buffered saline Tween (TBST) containing 5% powdered skim milk and reacted overnight with the following primary antibodies: anti-jagged1 (C-20, Santa Cruz Biotechnology, 1:1000). Horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology, 1:1000) was used to detect immunoreactive bands with Pierce ECL 2 (Thermo). Anti-beta actin antibody (HRP – ABCAM) was used as loading control.

Cell growth assay

GRMD and wild-type myoblasts were plated at 96-well plates in three different concentrations: 100, 1000 and 10000 cells/well. All samples were plated in triplicate. Cells were maintained in DMEM-HG (Dulbecco's modified Eagle's medium with high glucose; Gibco) supplemented with 20% (v/v) FBS (fetal bovine serum; Gibco) and anti-

anti (Gibco) at 37°C and 5% CO_2 for one week. Cell growth was measured using the CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT – Promega) following manufacture's protocol. Absorbance was recorded using the Synergy2 plate reader (BioTek).

Cardiotoxin injury

All mouse procedures were approved by the Boston Children's Hospital Animal Care and Use Committee (IACUC) under the animal protocol number 12-10-2287R. Wild type (C57B6/J) adult (2-4 month) male mice were house under pathogen free conditions. Mice were injured using an injection of 50 µl of 10 µM cardiotoxin isolated from *Naja mossambica mossambica* snake venom (Sigma-Aldrich, C-9759) into the right quadriceps muscle. The left, contralateral quadriceps muscle served as mock injected (PBS) control.

References

Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R. (2002). Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet *30*, 97-101.

Axelsson, E., Ratnakumar, A., Arendt, M.L., Maqbool, K., Webster, M.T., Perloski, M., Liberg, O., Arnemo, J.M., Hedhammar, A., and Lindblad-Toh, K. (2013). The genomic signature of dog domestication reveals adaptation to a starch-rich diet. Nature *495*, 360-364.

Browning, S.R., and Browning, B.L. (2007). Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet *81*, 1084-1097.

DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M.*, et al.* (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet *43*, 491-498.

Honeyman, K., Carville, K.S., Howell, J.M., Fletcher, S., and Wilton, S.D. (1999). Development of a snapback method of single-strand conformation polymorphism analysis for genotyping Golden Retrievers for the X-linked muscular dystrophy allele. American Journal of Veterinary Research *60*, 734-737.

Kang, H.M., Sul, J.H., Service, S.K., Zaitlen, N.A., Kong, S.Y., Freimer, N.B., Sabatti, C., and Eskin, E. (2010). Variance component model to account for sample structure in genome-wide association studies. Nat Genet *42*, 348-354.

Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and Haussler, D. (2002). The human genome browser at UCSC. Genome Res *12*, 996-1006.

Lawrence, C., and Mason, T. (2012). Zebrafish housing systems: a review of basic operating principles and considerations for design and functionality. ILAR J *53*, 179-191.

Li, H., and Durbin, R. (2010). Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics *26*, 589-595.

Liu, F., Kirichenko, A., Axenovich, T.I., van Duijn, C.M., and Aulchenko, Y.S. (2008). An approach for cutting large and complex pedigrees for linkage analysis. European journal of human genetics : EJHG *16*, 854-860.

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M.*, et al.* (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res *20*, 1297-1303.

Meeker, N.D., Hutchinson, S.A., Ho, L., and Trede, N.S. (2007). Method for isolation of PCR-ready genomic DNA from zebrafish tissues. Biotechniques *43*, 610, 612, 614.

Rosenbloom, K.R., Sloan, C.A., Malladi, V.S., Dreszer, T.R., Learned, K., Kirkup, V.M., Wong, M.C., Maddren, M., Fang, R., Heitner, S.G.*, et al.* (2013). ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res *41*, D56-63.

Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A *98*, 5116-5121.

Wellcome Trust Case Control, C. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature *447*, 661-678.

Yamamoto, M., Morita, R., Mizoguchi, T., Matsuo, H., Isoda, M., Ishitani, T., Chitnis, A.B., Matsumoto, K., Crump, J.G., Hozumi, K.*, et al.* (2010). Mib-Jag1-Notch signalling regulates patterning and structural roles of the notochord by controlling cell-fate decisions. Development *137*, 2527-2537.

Zatz, M., Vieira, N.M., Zucconi, E., Pelatti, M., Gomes, J., Vainzof, M., Martins-Bach, A.B., Garcia Otaduy, M.C., Bento Dos Santos, G., Amaro, E., Jr.*, et al.* (2015). A normal life without muscle dystrophin. Neuromuscul Disord.

Zucconi, E., Valadares, M.C., Vieira, N.M., Bueno, C.R., Jr., Secco, M., Jazedje, T., da Silva, H.C., Vainzof, M., and Zatz, M. (2009). Ringo: discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog. Neuromuscul Disord *20*, 64-70.